The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.
Participants must be assigned male sex at birth.
Report sexual activity with a someone assigned male at birth OR identify as GBM or TGW; be HIV-negative.
Identify as Hispanic and/or Latine .
Be able to provide informed consent in English or Spanish .
Individuals living with HIV.
Individuals assigned female sex at birth will be excluded.
Individuals who are currently taking oral PrEP from another source and are not willing to switch to lenacapavir for PrEP for the duration of the study will also be excluded.
Individuals who report a history of severe renal or hepatic disease or with clinical stigmata of either disease on physical exam as assessed by a study clinician will be excluded.
Duke University
Lead sponsor
Gilead Sciences
Collaborator